نتائج البحث - Emmanuelle Ferrant

  • يعرض 1 - 11 نتائج من 11
تنقيح النتائج
  1. 1
    Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues

    Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues حسب P. Fumoleau, Bruno Coudert, Nicolás Isambert, Emmanuelle Ferrant

    منشور في 2007
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    The Reversed Halo Sign: Pathognomonic Pattern of Pulmonary Mucormycosis in Leukemic Patients With Neutropenia?

    The Reversed Halo Sign: Pathognomonic Pattern of Pulmonary Mucormycosis in Leukemic Patients With Neutropenia? حسب C. Legouge, Denis Caillot, Marie‐Lorraine Chrétien, Ingrid Lafon, Emmanuelle Ferrant, S. Audia, P Pagès, M. Roques, L. Estivalet, L. Martin, Thomas Maitre, Jean Bastié, Frédéric Dalle

    منشور في 2013
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib

    Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib حسب David Ghez, Anne Calleja, Caroline Protin, Marine Baron, Marie‐Pierre Ledoux, Gandhi Damaj, Mathieu Dupont, Brigitte Dreyfus, Emmanuelle Ferrant, Charles Herbaux, Kamel Laribi, Ronan Le Calloch, Marion Malphettes, Franciane Paul, Laëtitia Souchet, Malgorzata Truchan-Graczyk, K. Delavigne, Caroline Dartigeas, Loïc Ysebaert

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?

    Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time? حسب Nicolas Gazeau, David Beauvais, Rémi Tilmont, Micha Srour, Emmanuelle Ferrant, Violaine Safar, Ludovic Fouillet, Pascale Flandrin‐Gresta, Nicolas Gower, Paul Chauvet, Nicolas Duployez, Benjamin Podvin, Julie Demaret, Sarah Huet, Pierre Sujobert, Hervé Ghesquières, Gandhi Damaj, Emmanuel Bachy, Franck Morschhauser, Ibrahim Yakoub‐Agha, Maël Heiblig, Pierre Sesques

    منشور في 2025
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified

    Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified حسب Estelle Bourbon, Delphine Maucort‐Boulch, Juliette Fontaine, Claire Mauduit, Pierre Sesques, Violaine Safar, Emmanuelle Ferrant, Camille Golfier, Dana Ghergus, Lionel Karlin, Anne Lazareth, Fadhela Bouafia, Gian Matteo Pica, Frédérique Orsini‐Piocelle, Clément Rocher, François‐Xavier Gros, Marie Parrens, Arthur Dony, Cédric Rossi, Hervé Ghesquières, Emmanuel Bachy, Alexandra Traverse‐Glehen, Clémentine Sarkozy

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

    Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chro... حسب Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak, Alan P Skarbnik, John M. Pagel, Ian W. Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett, Laura Fogliatto, Yair Herishanu, Versha Banerji, Steven Coutré, George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence Cymbalista, Jennifer A. Woyach, Emmanuelle Ferrant, William G. Wierda, Veerendra Munugalavadla, Ting Yu, Min Hui Wang, John C. Byrd

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Carta
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN

    Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN حسب Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak, Alan P Skarbnik, Krish Patel, Ian W. Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Marie Hughes, Laura Fogliatto, Yair Herishanu, Versha Banerji, George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence Cymbalista, John C. Byrd, Emmanuelle Ferrant, Alessandra Ferrajoli, William G. Wierda, Veerendra Munugalavadla, Catherine Wangui Wachira, Chuan‐Chuan Wun, Jennifer A. Woyach

    منشور في 2023
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

    Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatmen... حسب Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak, Alan P Skarbnik, John M. Pagel, Ian W. Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett, Laura Fogliatto, Yair Herishanu, Versha Banerji, Steven Coutré, George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence Cymbalista, Jennifer A. Woyach, Emmanuelle Ferrant, William G. Wierda, Veerendra Munugalavadla, Ting Yu, Min Hui Wang, John C. Byrd

    منشور في 2024
    احصل على النص الكامل احصل على النص الكامل
    Errata/Corrigenda
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Acalabrutinib-Obinutuzumab Improves Survival vs Chemoimmunotherapy in treatment-naive CLL in the 6-year Follow-up of ELEVATE-TN

    Acalabrutinib-Obinutuzumab Improves Survival vs Chemoimmunotherapy in treatment-naive CLL in the 6-year Follow-up of ELEVATE-TN حسب Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak, Alan P Skarbnik, Krish Patel, Ian W. Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Marie Hughes, Laura Fogliatto, Yair Herishanu, Versha Banerji, George Follows, Patricia Walker, Paolo Ghia, Ann Janssens, John C. Byrd, Emmanuelle Ferrant, Alessandra Ferrajoli, William G. Wierda, Catherine Wangui Wachira, Batul T. Suterwala, Paulo Miranda, Veerendra Munugalavadla, Chuan‐Chuan Wun, Jennifer A. Woyach

    منشور في 2025
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Commercial <scp>anti‐CD19 CAR</scp> T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center

    Commercial <scp>anti‐CD19 CAR</scp> T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center حسب Pierre Sesques, Emmanuelle Ferrant, Violaine Safar, Florent Wallet, Jérémie Tordo, Anthony Dhomps, Lionel Karlin, Gabriel Brisou, Marlène Vercasson, Carole Hospital‐Gustem, Vérane Schwiertz, Florence Ranchon, Catherine Rioufol, Marion Choquet, Pierre Sujobert, Dana Ghergus, Fadhela Bouafia, Camille Golfier, Hélène Lequeu, Anne Lazareth, Silvana Novelli, Perrine Devic, Alexandra Traverse Glehen, Sébastien Viel, Fabienne Venet, Valérie Mialou, Olivier Héquet, Adrien Chauchet, Yazid Arkam, Emmanuelle Nicolas‐Virelizier, Fréderic Peyrade, Doriane Cavalieri, Florence Ader, Hervé Ghesquières, Gilles Salles, Emmanuel Bachy

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

    6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial حسب Xavier Pivot, Gilles Romieu, Marc Debled, Jean‐Yves Pierga, Pierre Kerbrat, Thomas Bachelot, Alain Lortholary, Marc Espié, P. Fumoleau, Daniel Serin, Jean-Philippe Jacquin, Christelle Jouannaud, María Rios, Sophie Abadie‐Lacourtoisie, Laurence Venat‐Bouvet, L. Cany, Stéphanie Catala, David Khayat, Laëtitia Gambotti, Iris Pauporté, Céline Faure-Mercier, Sophie Paget‐Bailly, Julie Henriques, Jean Marie Grouin, Christine Piprot, L. Cals, L. Chaigneau, Francesca Demarchi, Trung Van Nguyen, Ulrike Stein, Cristian Villanueva, Bréau Jl, A. Chouahnia, Pierre Saintigny, François Boué, P deSaint-Hilaire, I Guimont, Nathalie Grossat, Bruno Valenza, E. Lévy, Jacques Médioni, Catherine Delbaldo, Jean‐Christophe Grenier, Damien Pouessel, Sandrine Lavau‐Denès, Claire Falandry, Cécile Fournel-Federico, Gilles Freyer, Sophie Tartas, V. Trillet-Lenoir, F. Bons, G Auclerc, Stéphanie Chièze, Nadia Raban, C. Tournigand, S. Trager-Maury, Guilhem Bousquet, C. Cuvier, Sylvie Giacchetti, Adam Hocini, C. Lemaignan, JL Misset, D. Avenin, C Beerblock, Joseph Gligorov, P. Rivera, Henri Roché, Philippe Bougnoux, Nawale Hajjaji, Olivier Capitain, R. Delva, P. Maillart, P Soulié, Hervé Bonnefoi, M Durand, Nicolas Madranges, L. Mauriac, P. Chollet, AF Dillies, Xavier Durando, J P Ferrière, C Mouret-Reynier, Nabholtz Jm, Isabelle Van Praagh, P. Cottu, Véronique Dièras, Axel Durieux, M Galotte, V. Girre, Sébastien Henry, Ida Iurisci, M Jouve, Valérie Laurence, L. Mignot, Sophie Piperno‐Neumann, Patricia Tresca, Bruno Coudert, Emmanuelle Ferrant, F. Mayer, AC Vanneuville

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: